References

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

10.3322/caac.21660 · 2021 · External reference

Palliative chemotherapy for advanced gastric cancer

10.1093/annonc/mdh422 · 2004 · External reference

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

10.1016/s0140-6736(10)61121-x · 2010 · External reference

Gastric cancer

10.1016/s0140-6736(16)30354-3 · 2016 · External reference

Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity

10.1111/cas.12966 · 2016 · External reference

Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study

10.1002/cac2.12214 · 2021 · External reference

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial

10.1016/s0140-6736(21)00797-2 · 2021 · External reference

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial

10.1016/s1470-2045(23)00515-6 · 2023 · External reference

Primary, adaptive, and acquired resistance to cancer immunotherapy

10.1016/j.cell.2017.01.017 · 2017 · External reference

Immunogenic cell death in cancer and infectious disease

10.1038/nri.2016.107 · 2017 · External reference

Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives

10.1016/j.ctrv.2022.102395 · 2022 · External reference

Clinicopathological features of gastric cancer with brain metastasis

10.1007/s005950070112 · 2000 · External reference

Brain metastases from gastric cancer

10.1177/03008916221084361 · 2023 · External reference

Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade

10.1126/scitranslmed.aac4925 · 2015 · External reference

Disitamab vedotin (RC48) plus toripalimab for HER2-expressing advanced gastric or gastroesophageal junction and other solid tumours: a multicentre, open label, dose escalation and expansion phase 1 trial

10.1016/j.eclinm.2023.102415 · 2024 · External reference

Disitamab vedotin plus programmed death-1 inhibitor for pre-treated HER2 overexpressed advanced gastric cancer: a multicentre retrospective real-world study

10.1080/07853890.2025.2569994 · 2025 · External reference

Trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2-positive (HER2+) esophageal, gastric or gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03 (DG-03) [Oral presentation

10.1016/j.annonc.2024.08.1467 · 2024 · External reference

First-line disitamab vedotin, tislelizumab, and S-1 in HER2-overexpressing advanced gastric or gastroesophageal junction adenocarcinoma: a single-arm, phase II trial

10.1200/jco-26-00277 · 2026 · External reference

Updated results from the trastuzumab deruxtecan 5.4 mg/kg triplet combination of DESTINY-Gastric03: first-line T-DXd with fluoropyrimidine and pembrolizumab in advanced or metastatic HER2-positive gastric cancer, gastroesophageal junction adenocarcinoma, or esophageal adenocarcinoma

10.1200/jco.2025.43.4_suppl.448 · 2025 · External reference

Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial

10.1016/s0140-6736(04)16250-8 · 2004 · External reference

Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a phase 3b/4 trial

10.1038/s41591-024-03261-7 · 2024 · External reference

Nivolumab in previously untreated melanoma without BRAF mutation

10.1056/nejmoa1412082 · 2015 · External reference

Long-term outcomes and retreatment among patients with previously treated, programmed death-ligand 1–positive, advanced non–small-cell lung cancer in the KEYNOTE-010 study

10.1200/jco.19.02446 · 2020 · External reference

The origins of memory T cells

10.1038/d41586-017-08280-8 · 2017 · External reference

Clinical outcomes of patients with advanced cancer and pre-existing autoimmune diseases treated with anti-PD-1 immunotherapy: a real-world transverse study

10.1634/theoncologist.2018-0618 · 2019 · External reference

Immune checkpoint immunotherapy for non-small cell lung cancer: benefits and pulmonary toxicities

10.1016/j.chest.2018.08.1048 · 2018 · External reference

Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer

10.1200/jco.2018.79.0006 · 2018 · External reference

Whole body irradiation—radiobiology or medicine

10.1259/0007-1285-26-305-234 · 1953 · External reference

Using immunotherapy to boost the abscopal effect

10.1038/nrc.2018.6 · 2018 · External reference

Role of local radiation therapy in cancer immunotherapy

10.1001/jamaoncol.2015.2756 · 2015 · External reference